dacarbazine has been researched along with sb 203580 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berger, MS; Haas-Kogan, DA; Hirose, Y; Katayama, M; Pieper, RO; Stokoe, D | 1 |
Gu, Y; Liu, J; Ma, L; Qi, J; Yu, W; Zhang, X | 1 |
2 other study(ies) available for dacarbazine and sb 203580
Article | Year |
---|---|
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Humans; Imidazoles; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Temozolomide | 2003 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Glioma; Heme Oxygenase-1; Humans; Imidazoles; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Temozolomide | 2015 |